Regeneron (NASDAQ:REGN)‘s stock had its “market perform” rating reaffirmed by research analysts at Raymond James Financial in a research report issued on Monday.
REGN has been the subject of several other reports. Jefferies Group reissued a “hold” rating and issued a $421.00 price objective on shares of Regeneron in a report on Friday, February 2nd. Morgan Stanley boosted their price objective on Regeneron from $401.00 to $415.00 and gave the company an “equal weight” rating in a report on Friday, February 9th. Guggenheim set a $530.00 price objective on Regeneron and gave the company a “buy” rating in a report on Friday, February 9th. Citigroup reissued a “neutral” rating and issued a $388.00 price objective (up from $380.00) on shares of Regeneron in a report on Tuesday, January 9th. Finally, BTIG Research reissued a “hold” rating on shares of Regeneron in a report on Tuesday, March 13th. Three analysts have rated the stock with a sell rating, seventeen have given a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $449.49.
Shares of Regeneron stock opened at $319.61 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. The stock has a market capitalization of $34,420.71, a P/E ratio of 23.83, a PEG ratio of 1.04 and a beta of 1.45. Regeneron has a fifty-two week low of $313.53 and a fifty-two week high of $543.55.
In other news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 14th. The stock was sold at an average price of $340.00, for a total value of $680,000.00. Following the transaction, the director now owns 14,000 shares of the company’s stock, valued at $4,760,000. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,000 shares of company stock valued at $1,705,640. Insiders own 10.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of REGN. Steward Partners Investment Advisory LLC lifted its position in Regeneron by 495.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 307 shares during the period. Pin Oak Investment Advisors Inc. acquired a new stake in Regeneron in the fourth quarter worth approximately $152,000. Advisory Services Network LLC lifted its position in Regeneron by 147.0% in the fourth quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares during the period. Vident Investment Advisory LLC acquired a new stake in Regeneron in the third quarter worth approximately $200,000. Finally, Mackenzie Financial Corp acquired a new stake in Regeneron in the fourth quarter worth approximately $204,000. Institutional investors and hedge funds own 66.39% of the company’s stock.
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Receive News & Ratings for Regeneron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron and related companies with MarketBeat.com's FREE daily email newsletter.